Hypertrophic Cardiomyopathy (HCM)
Hypertrophic cardiomyopathy (HCM is a complex, yet relatively common, genetic heart disease that occurs in approximately 1 in 500 individuals. It affects both genders and all races. The disease results in excessive thickening of the heart muscle—referred to as “hypertrophy”—which occurs most commonly in the septum (i.e. the muscular wall that separates the left and right lower chambers of the heart). In the majority of patients, this thickening begins during puberty, with little to no change in the thickness beyond early adulthood. However, symptoms from HCM can develop or worsen at any age, but most commonly occur during mid-life.
Doctors + Care Team
Title(s): Surgical Director, Structural Heart Program, Tufts Medical Center
Associate Professor, Tufts University School of Medicine
Department(s): CardioVascular Center, Cardiac Surgery
Appt. Phone: 617-636-5590
Fax #: 617-636-6410
Coronary artery disease, valve disease, atrial fibrillation, arrhythmia, hypertrophic cardiomyopathy, minimally invasive and hybrid therapies
View Full Profile for Lawrence S. Lee, MD, MBA
Research + Clinical Trials
This study is a double-blinded phase 2 clinical trial for a medication dedicated to treating patients with non-obstructive hypertrophic cardiomyopathy.
More information about research and clinical trials